Structural Similarities and Differences Between Neurofilament Proteins from Five Different Species As Revealed Using Monoclonal Antibodies
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Blood Neurofilament Light Chain: the Neurologist's Troponin?
biomedicines Review Blood Neurofilament Light Chain: The Neurologist’s Troponin? Simon Thebault 1,*, Ronald A. Booth 2 and Mark S. Freedman 1,* 1 Department of Medicine and the Ottawa Hospital Research Institute, The University of Ottawa, Ottawa, ON K1H8L6, Canada 2 Department of Pathology and Laboratory Medicine, Eastern Ontario Regional Laboratory Association and Ottawa Hospital Research Institute, University of Ottawa & The Ottawa Hospital, Ottawa, ON K1H8L6, Canada; [email protected] * Correspondence: [email protected] (S.T.); [email protected] (M.S.F.) Received: 4 November 2020; Accepted: 18 November 2020; Published: 21 November 2020 Abstract: Blood neurofilament light chain (NfL) is a marker of neuro-axonal injury showing promising associations with outcomes of interest in several neurological conditions. Although initially discovered and investigated in the cerebrospinal fluid (CSF), the recent development of ultrasensitive digital immunoassay technologies has enabled reliable detection in serum/plasma, obviating the need for invasive lumbar punctures for longitudinal assessment. The most evidence for utility relates to multiple sclerosis (MS) where it serves as an objective measure of both the inflammatory and degenerative pathologies that characterise this disease. In this review, we summarise the physiology and pathophysiology of neurofilaments before focusing on the technological advancements that have enabled reliable quantification of NfL in blood. As the test case for clinical translation, we then highlight important recent developments linking blood NfL levels to outcomes in MS and the next steps to be overcome before this test is adopted on a routine clinical basis. Keywords: neurofilament light chain; biomarkers; multiple sclerosis 1. Neurofilament Structure and Function Neurofilaments are neuronal-specific heteropolymers conventionally considered to consist of a triplet of light (NfL), medium (NfM) and heavy (NfH) chains according to their molecular mass [1]. -
Actin Cytoskeleton of Spread Fibroblasts Appears to Assemble at the Cell Edges
J. Cell Sd. 82, 235-248 (1986) 235 Printed in Great Britain © The Company of Biologists Limited 1986 ACTIN CYTOSKELETON OF SPREAD FIBROBLASTS APPEARS TO ASSEMBLE AT THE CELL EDGES TATJANA M. SVITKINA, ALEXANDER A. NEYFAKH, JR Laboratory of Molecular Biology and Bioorganic Chemistry, Moscow State University, Moscow 119899, USSR AND ALEXANDER D. BERSHADSKY All-Union Cancer Research Center, Academy of Medical Sciences, Moscow 115478, USSR SUMMARY The action of metabolic inhibitors on actin cytoskeleton of cultured quail embryo fibroblasts has been studied using electron microscopy of platinum replicas and immunofluorescence microscopy. Sodium azide as well as other inhibitors (oligomycin and dinitrophenol) caused the disassembly of all types of actin structures: actin meshwork at the cell active edges, microfilament sheath underlying the cell surface, and microfilament bundles. Studying the time- and dose-dependence of the destruction process we have found that the active edge meshwork and microfilament sheath are much more labile than microfilament bundles. After the removal of metabolic inhibitors actin cytoskeleton restoration begins at the cell edges. The first sign of this process is the formation of actin meshwork along the whole cell perimeter (l-10min of recovery). Sometimes fragments of this meshwork bend upwards forming ruffles. Later (10-20 min of recovery) the microfilament sheath appears at the cell periphery as a narrow band. The sheath seems to be formed from the edge meshwork, since ruffles in the process of transformation to sheath could be seen. During the following restoration the microfilament sheath gradually expands towards the cell centre. The last step of actin cytoskeleton restoration (60—120 min of recovery) is the formation of bundles. -
Differential Expression of Two Neuronal Intermediate-Filament Proteins, Peripherin and the Low-Molecular-Mass Neurofilament Prot
The Journal of Neuroscience, March 1990, fO(3): 764-764 Differential Expression of Two Neuronal Intermediate-Filament Proteins, Peripherin and the Low-Molecular-Mass Neurofilament Protein (NF-L), During the Development of the Rat Michel Escurat,’ Karima Djabali,’ Madeleine Gumpel,2 Franqois Gras,’ and Marie-Madeleine Portier’ lCollBne de France, Biochimie Cellulaire, 75231 Paris Cedex 05, France, *HBpital de la Salpktricke, Unite INSERM 134, 75651Paris Cedex 13, France The expression of peripherin, an intermediate filament pro- and Freeman, 1978), now more generally referred to respectively tein, had been shown by biochemical methods to be local- as high-, middle-, and low-molecular-mass NFP (NF-H, NF-M, ized in the neurons of the PNS. Using immunohistochemical and NF-L). These proteins are expressed in most mature neu- methods, we analyzed this expression more extensively dur- ronal populations belonging either to the CNS or to the PNS; ing the development of the rat and compared it with that of developing neurons generally do not express any of them until the low-molecular-mass neurofilament protein (NF-L), which they become postmitotic (Tapscott et al., 198 la). is expressed in every neuron of the CNS and PNS. We, however, described another IFP with a molecular weight The immunoreactivity of NF-L is first apparent at the 25 of about 57 kDa, which we had first observed in mouse neu- somite stage (about 11 d) in the ventral horn of the spinal roblastoma cell lines and which was also expressed in rat pheo- medulla and in the posterior part of the rhombencephalon. chromocytoma PC1 2 cell line. -
Wieslab Request Form - Neurology Neurology SEND TO: Wieslab AB CONTACT T +46 (0)40 - 53 76 60 P.O
Wieslab Request Form - Neurology Neurology SEND TO: Wieslab AB CONTACT T +46 (0)40 - 53 76 60 P.O. Box 50117, SE-202 11 Malmö, Sweden [email protected] F +46 (0)40 - 43 28 90 REQUESTING DOCTOR/CLINIC BILL TO / INVOICE ADDRESS PATIENT DATA Postal address for test result report Only doctors, laboratories and hospital Full name: administration can be invoiced Birth date, Identity number: GENDER Man Woman Other SAMPLING DATE REFERENCE NUMBER / SAMPLING MATERIAL Serum CSF EDTA-Plasma EDTA-Whole blood COST CENTER REQUESTING DOCTOR SPECIMEN COLLECTION INFORMATION • For autoantibody assays, blood should be collected in plain tubes (serum tubes) without additives. Name: • 3 mL serum after centrifuging 7 mL blood (1300-1800g for 10 min) is enough for approx. 15 tests. • Keep samples cold until transport. Transport samples at room temperature by ordinary mail or with cold packs if long transportation (>24h). Email: • 3 mL CSF should be collected and transported in polypropylene tubes; enough for approx. 10 tests. • 2,5 mL EDTA-whole blood is needed for HLA determination. Phone: • 0,5 mL CSF is needed for each biomarker (transport frozen). • For more information about sampling please see: www.wieslab.com/diagnostic-services/sampling Comments (Patient history etc.) The healthcare provider submitting the sample(s) with this request form hereby confirms that the patient (or the patient’s guardian or trustee, if applicable) has been informed that the samples may be retained by Wieslab AB for a period of up to 5 years for the purpose of conducting further analyses in order to make a diagnosis, and that Wieslab AB intends to retain samples for a period of up to 5 years for the purpose of the Svar Life Science AB/Wieslab AB’s future development of analysis methods and its business activities. -
HTS-Tubulin Polymerization Assay Biochem Kit™
The Protein Manual Experts Cytoskeleton, Inc. V 8.0 HTS-Tubulin Polymerization Assay Biochem Kit™ (>97% pure tubulin, Porcine Tubulin) Cat. # BK004P Phone: (303) 322.2254 Fax: (303) 322.2257 Customer Service: [email protected] cytoskeleton.com Technical Support: [email protected] cytoskeleton.com Page 2 Manual Contents Section I: Introduction About Tubulin -------------------------------------------------------------------------- 5 About the BK004P polymerization Assay -------------------------------------- 6-7 Comparison of Polymerization Assays ----------------------------------------- 8-9 Section II: Purchaser Notification ------------------------------------------------------------ 10 Section III: Kit Contents ------------------------------------------------------------------------- 11-12 Section V: Reconstitution and Storage of Components ----------------------------- 13 Section IV: Important Technical Notes Notes on Updated version --------------------------------------------------------- 14 Spectrophotometer settings ------------------------------------------------------- 14 Spectrophotometer pathlength---------------------------------------------------- 15 Temperature & time dependence of polymerization ------------------------ 15 Recommended pipetting technique --------------------------------------------- 15-16 Tubulin protein stability ------------------------------------------------------------- 16 Test compound or protein preparation ------------------------------------------ 16-17 Section VI: Assay Protocol -
Transiently Structured Head Domains Control Intermediate Filament Assembly
Transiently structured head domains control intermediate filament assembly Xiaoming Zhoua, Yi Lina,1, Masato Katoa,b,c, Eiichiro Morid, Glen Liszczaka, Lillian Sutherlanda, Vasiliy O. Sysoeva, Dylan T. Murraye, Robert Tyckoc, and Steven L. McKnighta,2 aDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390; bInstitute for Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology, 263-8555 Chiba, Japan; cLaboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0520; dDepartment of Future Basic Medicine, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, Japan; and eDepartment of Chemistry, University of California, Davis, CA 95616 Contributed by Steven L. McKnight, January 2, 2021 (sent for review October 30, 2020; reviewed by Lynette Cegelski, Tatyana Polenova, and Natasha Snider) Low complexity (LC) head domains 92 and 108 residues in length are, IF head domains might facilitate filament assembly in a manner respectively, required for assembly of neurofilament light (NFL) and analogous to LC domain function by RNA-binding proteins in the desmin intermediate filaments (IFs). As studied in isolation, these IF assembly of RNA granules. head domains interconvert between states of conformational disor- IFs are defined by centrally located α-helical segments 300 to der and labile, β-strand–enriched polymers. Solid-state NMR (ss-NMR) 350 residues in length. These central, α-helical segments are spectroscopic studies of NFL and desmin head domain polymers re- flanked on either end by head and tail domains thought to be veal spectral patterns consistent with structural order. -
Microtubule-Associated Protein Tau (Molecular Pathology/Neurodegenerative Disease/Neurofibriliary Tangles) M
Proc. Nati. Acad. Sci. USA Vol. 85, pp. 4051-4055, June 1988 Medical Sciences Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-associated protein tau (molecular pathology/neurodegenerative disease/neurofibriliary tangles) M. GOEDERT*, C. M. WISCHIK*t, R. A. CROWTHER*, J. E. WALKER*, AND A. KLUG* *Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, United Kingdom; and tDepartment of Psychiatry, University of Cambridge Clinical School, Hills Road, Cambridge CB2 2QQ, United Kingdom Contributed by A. Klug, March 1, 1988 ABSTRACT Screening of cDNA libraries prepared from (21). This task is made all the more difficult because there is the frontal cortex ofan zheimer disease patient and from fetal no functional or physiological assay for the protein(s) of the human brain has led to isolation of the cDNA for a core protein PHF. The only identification so far possible is the morphol- of the paired helical fiament of Alzheimer disease. The partial ogy of the PHFs at the electron microscope level, and here amino acid sequence of this core protein was used to design we would accept only experiments on isolated individual synthetic oligonucleotide probes. The cDNA encodes a protein of filaments, not on neurofibrillary tangles (in which other 352 amino acids that contains a characteristic amino acid repeat material might be occluded). One thus needs a label or marker in its carboxyl-terminal half. This protein is highly homologous for the PHF itself, which can at the same time be used to to the sequence ofthe mouse microtubule-assoiated protein tau follow the steps of the biochemical purification. -
Neurofilaments: Neurobiological Foundations for Biomarker Applications
Neurofilaments: neurobiological foundations for biomarker applications Arie R. Gafson1, Nicolas R. Barthelmy2*, Pascale Bomont3*, Roxana O. Carare4*, Heather D. Durham5*, Jean-Pierre Julien6,7*, Jens Kuhle8*, David Leppert8*, Ralph A. Nixon9,10,11,12*, Roy Weller4*, Henrik Zetterberg13,14,15,16*, Paul M. Matthews1,17 1 Department of Brain Sciences, Imperial College, London, UK 2 Department of Neurology, Washington University School of Medicine, St Louis, MO, USA 3 a ATIP-Avenir team, INM, INSERM , Montpellier university , Montpellier , France. 4 Clinical Neurosciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom 5 Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Québec, Canada 6 Department of Psychiatry and Neuroscience, Laval University, Quebec, Canada. 7 CERVO Brain Research Center, 2601 Chemin de la Canardière, Québec, QC, G1J 2G3, Canada 8 Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland. 9 Center for Dementia Research, Nathan Kline Institute, Orangeburg, NY, 10962, USA. 10Departments of Psychiatry, New York University School of Medicine, New York, NY, 10016, 11 Neuroscience Institute, New York University School of Medicine, New York, NY, 10016, USA. 12Department of Cell Biology, New York University School of Medicine, New York, NY, 10016, USA 13 University College London Queen Square Institute of Neurology, London, UK 14 UK Dementia Research Institute at University College London 15 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden 16 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden 17 UK Dementia Research Institute at Imperial College, London * Co-authors ordered alphabetically Address for correspondence: Prof. -
Expression of Neurofilament Subunits in Neurons of the Central and Peripheral Nervous System: an Lmmunohistochemical Study with Monoclonal Antibodies
The Journal of Neuroscience March 1986, 6(3): 650-660 Expression of Neurofilament Subunits in Neurons of the Central and Peripheral Nervous System: An lmmunohistochemical Study with Monoclonal Antibodies J. Q. Trojanowski, N. Walkenstein, and V. M.-Y. Lee The Division of Neuropathology, Department of Pathology and Laboratory Medicine, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 The extent to which all neurofilament (NF) subunits (NF68, 1983; Shaw et al., 1981). For example, Sharp et al. (1982) were NF150, NF200) are expressed by different populations of ma- able to distinguish two classesof neurons in PNS gangliabased ture CNS and PNS neurons is controversial. We addressed this on the presenceor absenceof NF proteins. issue in immunohistochemical studies of mature bovine tissues The absenceof one or more NF subunits in some neurons using monoclonal antibodies specific for each bovine NF sub- would necessitatedifferent hypothesesconcerning the structure unit. and function of NFs. Alternatively, microheterogeneityamong All three NF subunits were detected in the perikarya and NF proteins due to the phosphorylation state of thesepolypep- neurites of both CNS and PNS neurons; they were seen in near- tides, or as a consequenceof unknown mechanisms,may ac- ly all PNS neuronal perikarya, and in all identifiable CNS and count for the apparent variable expressionof theseproteins in PNS axons. Most, but not all, CNS neuronal perikarya con- neurons(Goldstein et al., 1983; Nixon et al., 1982; Sternberger tained each of these NF antigens. CNS neurons devoid of im- and Sternberger, 1983). Other explanations, such as limitations munodetectable NF antigens were generally small. The pres- in the methods used to identify NF subunits in situ, are also ence of low levels of NF antigens in neurons with scant perikaryal possible(Hickey et al., 1983). -
INITIAL EXPRESSION of NEUROFILAMENTS and VIMENTIN in the CENTRAL and PERIPHERAL NERVOUS SYSTEM of the MOUSE EMBRYO in Vivol
0270-6474/84/0408-2080$02.00/O The Journal of Neuroscience Copyright 0 Society for Neuroscience Vol. 4, No. 8, pp. 2080-2094 Printed in U.S.A. August 1984 INITIAL EXPRESSION OF NEUROFILAMENTS AND VIMENTIN IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEM OF THE MOUSE EMBRYO IN VIVOl PHILIPPE COCHARD’ AND DENISE PAULIN* Institut d%mbryologie du Centre National de la Recherche Scientifique et du Collkge de France, 94130 Nogent-sur-Marne, France and *Laboratoire de Gdn&ique Cellulaire, Institut Pasteur, 75015 Paris, France Received December 9,1983; Accepted February 9, 1984 Abstract The appearance of neurofilaments (NFs) and vimentin (Vim) in the nervous system of the mouse embryo was documented using immunohistochemical techniques. The three NF protein subunits appear early and simultaneously in central and peripheral neurons at 9 to 10 days of gestation. The onset of NF expression is concomitant with axon elongation and correlates extremely well with neurofibrillar differentiation and, in the case of autonomic ganglia, with the expression of adrenergic neurotransmitter properties. In the central and peripheral nervous system, NF expression is preceded by that of Vim, and both types of intermediate filaments coexist within the same cell for a short period of time. Specific markers of neuronal and glial cell types are powerful cases, they have revealed common epitopes shared by the tools for studying the mechanisms generating cellular diversi- various classes of IF (Pruss et al., 1981; Dellagi et al., 1982; fication in the nervous system. In recent years, intermediate Gown and Vogel, 1982 and, in the NF class, by the various NF filaments (IFS), a particular class of cytoskeletal proteins, have subunits (Willard and Simon, 1981; Lee et al., 1982; Goldstein attracted much interest, largely because of their polymorphism; et al., 1983). -
Cytoskeleton Cytoskeleton
CYTOSKELETON CYTOSKELETON The cytoskeleton is composed of three principal types of protein filaments: actin filaments, intermediate filaments, and microtubules, which are held together and linked to subcellular organelles and the plasma membrane by a variety of accessory proteins Muscle Contraction • Skeletal muscles are bundles of muscle fibers • Most of the cytoplasm consists of myofibrils, which are cylindrical bundles of two types of filaments: thick filaments of myosin (about 15 run in diameter) and thin filaments of actin (about 7 nm in diameter). • Each myofibril is organized as a chain of contractile units called sarcomeres, which are responsible for the striated appearance of skeletal and cardiac muscle. Structure of muscle cells Sarcomere • The ends of each sarcomere are defined by the Z disc. • Within each sarcomere, dark bands (called A bands because they are anisotropic when viewed with polarized light) alternate with light bands (called I bands for isotropic). • The I bands contain only thin (actin) filaments, whereas the A bands contain thick (myosin) filaments. • The myosin and actin filaments overlap in peripheral regions of the A band, whereas a middle region (called the H zone) contains only myosin. Muscle contraction • The basis for understanding muscle contraction is the sliding filament model, first proposed in 1954 both by Andrew Huxley and Ralph Niedergerke and by Hugh Huxley and Jean Hanson • During muscle contraction each sarcomere shortens, bringing the Z discs closer together. • There is no change in the width of the A band, but both the I bands and the H zone almost completely disappear. • These changes are explained by the actin and myosin filaments sliding past one another so that the actin filaments move into the A band and H zone. -
Formation of Hirano Bodies in Cell Culture 1941
Research Article 1939 Formation of Hirano bodies in Dictyostelium and mammalian cells induced by expression of a modified form of an actin-crosslinking protein Andrew G. Maselli, Richard Davis, Ruth Furukawa and Marcus Fechheimer* Department of Cellular Biology, University of Georgia, Athens, Georgia 30602, USA *Author for correspondence (e-mail: [email protected]) Accepted 26 February 2002 Journal of Cell Science 115, 1939-1952 (2002) © The Company of Biologists Ltd Summary We report the serendipitous development of the first pathological conditions. Furthermore, expression of the cultured cell models of Hirano bodies. Myc-epitope-tagged CT fragment in murine L cells results in F-actin forms of the 34 kDa actin bundling protein (amino acids 1- rearrangements characterized by loss of stress fibers, 295) and the CT fragment (amino acids 124-295) of the 34 accumulation of numerous punctate foci, and large kDa protein that exhibits activated actin binding and perinuclear aggregates, the Hirano bodies. Thus, failure to calcium-insensitive actin filament crosslinking activity regulate the activity and/or affinity of an actin crosslinking were expressed in Dictyostelium and mammalian cells to protein can provide a signal for formation of Hirano bodies. assess the behavior of these modified forms in vivo. More generally, formation of Hirano bodies is a cellular Dictyostelium cells expressing the CT-myc fragment: (1) response to or a consequence of aberrant function of the form ellipsoidal regions that contain ordered assemblies of actin cytoskeleton. The results reveal that formation of F-actin, CT-myc, myosin II, cofilin and α-actinin; (2) grow Hirano bodies is not necessarily related to cell death.